While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

This resulted in seven deaths and multiple injuries to various people, again, because of the inaccuracy in a specific set of ...

Wearable makers like Apple, Samsung, Garmin, Google have long chased what might be the holy grail of health tech: ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...

DexCom, Inc. , the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO Jake Leach, who assumed his ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...